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AbstrACt
Objectives We sought to determine the unique and 
shared contributions of clinical, neurocognitive and 
demographic factors to functional impairment in a large, 
transdiagnostic, clinical cohort of adolescents and young 
adults.
Design Cross-sectional baseline data from a prospective, 
cohort study.
setting Help-seeking youth referred from outpatient 
services were recruited to the Brain and Mind Youth Cohort 
(2008–2016) in Sydney, Australia.
Participants In total, 1003 outpatients were recruited, 
aged between 12 and 36 years (mean= 20.4 years, 54% 
female), with baseline diagnoses of affective, psychotic, 
developmental or behavioural disorders.
Interventions Treatment as usual.
Primary outcome measures Social and occupational 
functioning was used to index level of functional 
impairment. Structural equation modelling was used 
to examine associations between neurocognition, core 
clinical symptoms and alcohol and substance use, and 
clinician-rated and researcher-rated functional impairment. 
Moderator analyses were conducted to determine the 
potential influence of demographic and clinical factors (eg, 
medication exposure).
results Independent of diagnosis, we found that 
neurocognitive impairments, and depressive, anxiety 
and negative symptoms, were significantly associated 
with functioning. The association of neurocognition with 
social and occupational functioning remained significant 
even when constraining for age (15–25-year-olds only) or 
diagnosis (affective disorders only) in the final model.
Conclusions This study demonstrated that, in a clinically 
representative sample of youth, the key determinants 
of functioning may not be disorder specific. Further, 
evidence of neurocognitive dysfunction suggests that 
interventions that target cognition and functioning should 
not necessarily be reserved just for older adults with 
established illness.
IntrODuCtIOn 
In recent decades, early intervention services 
for youth with emerging mental disorders 
have extended their targets beyond those 
at risk of psychosis to also encompass those 
presenting with mood as well as other develop-
mental and anxiety disorders. This approach 
creates several significant challenges. For 
example, some youth with depressive and 
anxiety disorders will ultimately develop 
psychotic or bipolar disorders; likewise, only 
a proportion of those receiving a diagnosis of 
bipolar disorders will consistently receive this 
diagnosis over the following 10 years.1 The 
lack of diagnostic stability in help-seeking 
youth reflects the evolving disease process 
and means that the illness trajectory is less 
certain than for older adults with established 
illness.2 3 From a research perspective, the 
use of dimensional approaches to phenom-
enology has helped us to understand illness 
progression in these early clinical stages, 
while from a clinical perspective, care and 
treatment have increasingly considered 
transdiagnostic interventions addressing 
core factors that may influence prognosis 
irrespective of cross-sectional diagnosis (eg, 
strengths and limitations of this study
 ► This was one of the largest studies to date (n>1000) 
to examine the associations between a broad range 
of illness characteristics and functional impairment 
in a mostly adolescent and young adult, clinical 
sample.
 ► Given the transdiagnostic approach, this study was 
equipped to disentangle the shared and unique 
associations between core illness phenotypes and 
functional impairment across a range of common 
mental disorders.
 ► The use of latent-variable, structural equation 
modelling controlled for aspects of measurement 
imprecision.
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anxiety, depressive or negative symptoms; sleep distur-
bances).4 5 These approaches have highlighted that, in 
youth, a more meaningful measure of outcome may be 
functioning rather than change in diagnosis-specific 
symptoms. There is evidence to support this approach 
as level of functioning or disengagement (eg, not being 
in education, employment or training, referred to as 
being NEET) is associated with early transition to major 
mental disorder6 and with poor outcome of acute illness 
episodes.7 8 However, to optimise interventions that 
target functioning it is important to understand the 
factors that contribute to level of functioning at clinical 
presentation. For instance, in addition to transdiagnostic 
symptom dimensions, it is likely that other factors such 
as neurocognitive functioning and alcohol or substance 
use will also affect overall functioning. Disentangling 
the contribution and magnitude of any effects of these 
factors on functioning is important to determine which 
factors may be amenable to modification and allow clini-
cians to design a multidimensional intervention package.
The proposal that social and occupational functioning 
should be a primary target for mental health interven-
tions is not new and is increasingly promoted for older 
adults with established illness. For example, senior policy 
experts in the USA have stipulated that recovery-oriented 
treatments should form the overarching goal of mental 
healthcare and the foundation of strategic health policy.9 
The recognition that more personalised interventions are 
urgently needed to enhance functioning and quality of 
life rather than simply targeting diagnosis-specific symp-
toms in a one-size-fits-all approach is also emphasised by 
the WHO.10 Given this interest in enhancement of func-
tioning across all stages of mental illness and for youth 
and adults presenting to mental health services, it is 
therefore useful to examine the role of other key clinical 
(eg, medication exposure) and demographic factors (eg, 
age, gender) in determining functioning which would 
contribute to prognosis and attempts at personalised 
medicine.
Most path modelling studies to date have used small, 
single-diagnosis or dual-diagnosis cohorts, predomi-
nantly in individuals with a chronic mental illness. Find-
ings consistently demonstrate that neurocognition and 
negative symptoms are robust predictors of functional 
outcome in schizophrenia and bipolar disorder.7 11 12 By 
contrast, the impact of affective and positive symptoms on 
functioning remains more equivocal. More recently, these 
findings have been replicated in large cohort studies,13 14 
although the vast majority of existing studies have focused 
exclusively on schizophrenia. There have been no 
well-powered studies examining a mental disorder other 
than schizophrenia, such as affective disorders, despite 
depression being the leading cause of disability world-
wide.15 Studies have also largely sidestepped the issue 
of psychotropic medication use. Furthermore, given 
that more than 75% of mental illnesses emerge before 
the age of 25,3 examining younger cohorts is critically 
important for the development of novel approaches to 
early intervention since most studies to date have targeted 
older individuals.15
In order to build on prior research, a transdiagnostic 
and dimensional approach is ideally positioned to disen-
tangle the factors associated with functioning. Key to this 
research strategy is the examination of shared constructs 
(eg, neurocognition) with clear links to pathophysi-
ology16–18 which can inform novel therapeutics that target 
specific neural circuitries.17 19 Transdiagnostic studies are 
also able to harness the variance across disorders, with 
the goal of developing robust, unifying models that are 
explanatory in nature.2 Data showing that physiological 
and genetic risk factors for mental illness extend across, 
rather than are bound by, traditional diagnoses,20 further 
supports this paradigm, as does the frequent prescrip-
tion of psychotropic medications for off-label use across 
diagnostic boundaries.21 Transdiagnostic studies are also 
superior to single-diagnosis case–control studies in that 
they can determine which relationships are shared across 
various diagnoses and which are unique to a particular 
disorder.
In this study, we sought to determine whether (1) 
neurocognition, (2) core clinical dimensions and (3) 
alcohol and substance use are associated with social and 
occupational functioning and the magnitude of these 
associations. The rationale for examining clinical symp-
toms and functioning alongside neurocognition, sleep 
changes and substance use is underscored by a recent 
systematic review highlighting the transdiagnostic rele-
vance of these key domains in youth with mental illness.22 
In keeping with prior research,7 12 23 it was hypothesised 
that neurocognition and negative symptoms would make 
the greatest contribution to level of social and occupa-
tional functioning irrespective of the cross-sectional 
diagnosis applied to cases at the time of inclusion in the 
cohort. Given the high degree of heterogeneity expected 
in a transdiagnostic youth sample, we secondarily sought 
to determine the influence of demographic (eg, age, 
gender) and clinical factors (eg, diagnosis, medication 
exposure) on findings.
MethODs
Data included in the current study represent the baseline 
assessments conducted at entry to the cohort study and 
were collected between April 2008 and May 2016.
Participants
Participants were recruited into the Brain and Mind Youth 
Cohort from youth mental health outpatient services at 
the Brain and Mind Centre.24 25 Referred participants 
were 12–36 years of age and presented with a major affec-
tive, psychotic or developmental/behavioural syndrome. 
Participants were excluded if they (or their guardians, if 
aged under 16 years) were unwilling or unable to provide 
written informed consent, or if they had a pre-existing 
neurological condition, clinically assessed impaired 
English language skills and/or intellectual disability 
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that precluded completion of study self-ratings. Eligible 
participants completed a series of observer and self-rated 
questionnaires.
Procedure
Treating clinicians recorded clinical diagnoses, and 
these were reviewed at consensus meetings by senior, 
treating psychiatrists (eg, IBH, EMS) and formal diag-
noses recorded based on the Diagnostic and Statistical 
Manual of Mental Disorders - Fourth Edition (Text Revi-
sion) (DSM-IV-TR); table 1 provides details of diagnoses 
and sample characteristics). Any disagreements in diag-
nosis were resolved at these consensus meetings with the 
relevant treating team. All participants received their 
prescribed course of medications and interventions, as 
independently determined in consultation with their 
treating clinicians.
Board-certified treating clinicians (ie, consultant 
psychiatrists, clinical psychologists, mental health nurses) 
provided an evaluation of each participant’s social and 
occupational functioning. Next, board-certified clin-
ical psychologists, clinical neuropsychologists or trained 
research psychologists (ie, graduate-level academic 
psychologists, supervised by RSCL to ensure a sufficient 
level of inter-rater reliability) conducted structured clin-
ical interviews, neuropsychological testing, as well as an 
additional assessment of social and occupational func-
tioning to improve the reliability of this single, clini-
cian-rated score (approximately 80% were conducted 
within a month of the treating clinician assessment).
Table 1 Demographic, clinical and functional characteristics across diagnostic subgroups
Depression*
(n=449)
Bipolar†
(n=178)
Psychosis ‡ 
(n = 193) 
Anxiety§
(n=109)
Dev/behav¶
(n=74)
M SD M SD M SD M SD M SD
Age 19.8 4.3 21.6 4.8 22.2 4.6 19.9 4.8 17.0 4.6
Education (years) 11.6 2.4 12.3 2.2 12.0 2.4 11.5 2.7 10.0 2.8
BPRS depression (/7) 2.4 0.8 2.2 0.8 2.1 0.9 2.3 0.9 1.7 0.7
BPRS mania (/7) 1.3 0.5 1.5 0.6 1.4 0.4 1.4 0.4 1.5 0.7
BPRS positive (/7) 1.3 0.4 1.4 0.5 1.8 0.7 1.4 0.5 1.3 0.4
BPRS negative (/7) 1.5 0.6 1.3 0.5 1.9 0.8 1.5 0.7 1.5 0.6
BRPS disorientation (/7) 1.2 0.5 1.1 0.5 1.2 0.6 1.2 0.5 1.2 0.5
HDRS sleep (/6) 2.0 1.8 1.7 1.7 1.3 1.6 1.5 1.5 1.8 1.7
AUDIT alcohol use (/40) 6.8 7.4 9.0 8.4 6.2 8.0 4.4 6.4 5.1 7.5
WHO-ASSIST tobacco use (/4) 1.3 1.6 1.6 1.7 1.7 1.9 1.0 1.5 1.4 1.7
WHO-ASSIST cannabis use (/4) 0.7 1.2 0.7 1.3 0.4 1.0 0.4 0.9 0.7 1.3
WHO-ASSIST other illicit substance 
use (/4)
0.1 0.3 0.1 0.3 0.1 0.2 0.1 0.3 0.1 0.3
SOFAS 61.8 10.7 63.9 11.5 55.9 12.1 63.2 11.1 61.7 9.8
N % N % N % N % N %
Gender (female) 277 61.7 129 72.5 58 30.1 58 53.2 20 27.0
Medicated** 231 60.0 128 77.6 140 77.3 37 45.7 32 49.2
Antidepressants 201 52.2 63 38.2 55 30.4 25 30.9 12 18.5
Lithium/anticonvulsants 28 7.3 69 41.8 24 13.3 6 7.4 3 4.6
Antipsychotics 71 18.4 77 46.7 125 69.1 9 11.1 8 12.3
Stimulants 14 3.6 7 4.2 3 1.7 4 4.9 14 21.5
*Major depressive disorder (n=313), dysthymic disorder (n=4), depressive disorder not otherwise specified (n=132).
†Bipolar I disorder (n=13), bipolar II disorder (n=25), cyclothymic disorder (n=1), bipolar disorder not otherwise specified (n=139).
‡Schizophrenia (n=53), schizophreniform disorder (n=15), schizoaffective disorder (n=26), brief psychotic disorder (n=11), substance-induced 
psychotic disorder (n=14), psychotic disorder not otherwise specified (n=74).
§Panic disorder (n=4), social phobia (n=29), obsessive-compulsive disorder (n=11), post-traumatic stress disorder (n=5), generalised anxiety 
disorder (n=60).
¶Asperger’s disorder (n=16), attention-deficit/hyperactivity disorder (n=47), conduct disorder (n=7), oppositional defiant disorder (n=4).
**Medication data were available in 877 individuals (87.4%), with missing data for the typologies of depression (n=64), bipolar (n=13), 
psychosis (n=12), anxiety (n=28), developmental (n=9).
AUDIT, Alcohol Use Disorders Identification Test; BPRS, Brief Psychiatric Rating Scale; dev/behav, developmental/behavioural; HDRS, 
Hamilton Depression Rating Scale; SOFAS, Social and Occupational Functioning Assessment Scale; WHO-ASSIST, WHO–Alcohol, Smoking 
and Substance Involvement Screening Test. 
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Measures
 ► Social and occupational functioning was indexed using 
the Social and Occupational Assessment Functioning 
Scale (SOFAS).26 Scores were averaged across the 
treating clinician and researcher assessments (intr-
aclass correlation coefficient=0.70), as previously 
done.27 This composite score was derived to obtain a 
more reliable estimate of real-world functioning and, 
secondarily, to conserve free parameters and increase 
stability of parameter estimates.23 28 A higher score 
denotes better functioning.
 ► Neurocognition was assessed using a broad neuropsy-
chological battery with demographic normative-ad-
justments (previously described23) and was chosen on 
the basis of sound psychometric properties29 and rele-
vance to the disorders under study.30 Predicted IQ was 
estimated using the Wechsler Test of Adult Reading 
or Wide Range Achievement Test—fourth edition 
(for participants younger than 16 years). Psychomotor 
speed and mental flexibility were measured using 
Trail Making Test—Part A (TMT-A) and Part B (TMT-
B). Verbal learning and memory were indexed using 
the five-trial total and delayed recall scores from the 
Rey Auditory Verbal Learning Test. Verbal fluency was 
composed of the letter (F-A-S) and category (animals) 
fluency subtests of the Controlled Oral Word Associa-
tion Test. A higher score indicates better functioning.
 ► Core clinical symptom dimensions were measured across 
two validated scales. Symptoms were rated on the 
expanded Brief Psychiatric Rating Scale (BPRS) 
using empirically derived symptom subscores (depres-
sion and anxiety, mania, positive symptoms, negative 
symptoms and disorientation31). The BPRS does not 
capture sleep profiles as a separate dimension so, as in 
previous studies,32 disturbed sleep was indexed using 
the sum of the three sleep items from the Hamilton 
Depression Rating Scale.33 A higher score denotes 
greater severity of symptoms.
 ► Alcohol and substance use were measured across two 
validated scales. Alcohol use was indexed using the 
Alcohol Use Disorders Identification Test34 total 
score. Substance use for tobacco, cannabis and other 
illicit substances was measured using the ‘current 
frequency’ subscale (past 3 months) from the WHO–
Alcohol, Smoking and Substance Involvement 
Screening Test questionnaire.35 A higher score indi-
cates greater alcohol or substance use.
Patient and public involvement
Participants were not involved in the development of 
research question(s), design and outcome measures, nor 
was the study informed by their priorities, experience 
and preferences. We did not formally assess the burden 
of time required to participate in the research.
Data analysis
Statistical analyses were conducted using IBM SPSS V.20.0 
and AMOS V.20.0. Maximum likelihood estimation 
(MLE) was employed for all structural equation model-
ling (SEM) analyses. MLE was chosen as it is the most 
robust approach in the potential event of statistical 
assumption violations and performs best in heteroge-
neous samples.36 Missing data were also handled by MLE 
which does not involve data imputation, but uses all avail-
able data to compute maximum likelihood estimates. 
Diagnostic and demographic data were available for all 
participants. In total, 9.1% of data were missing for func-
tioning, 18.8% for neurocognition, 12.7% for clinical 
symptoms and disturbed sleep, and 17.7% were missing 
for alcohol and substance use. Each analysis had >80% of 
cases with complete data. Additional analyses revealed 
that data were not missing at random, and missing 
data were more likely to occur in younger participants 
(Welch’s F(1102.54)=4.85, p<0.05) and in those with an 
anxiety disorder (χ2(4)=26.09, p < 0.001), although the 
effect sizes were small (Cohen’s d=0.26 and Cramer’s 
V=0.16, respectively).
Normality was assessed through inspection of Q-Q plots, 
given inferential measures of non-normality (eg, Shap-
iro-Wilk statistic) are overly sensitive in large datasets and 
almost always return a significant finding.37 All endoge-
nous variables (eg, SOFAS) met normality assumptions 
on visual inspection. Based on visual inspection of the 
frequency histograms and assessment of the Q-Q plot, 
the predictor/exogenous variables that departed from 
normality were positive symptoms, negative symptoms, 
mania, disorientation, TMT-A and TMT-B which were all 
observed to have a slight positive skew (no others were 
skewed). Prior studies have found that MLE methods are 
robust in cases where variables depart from normality 
where n>600, as in the present case.38 However, other 
approaches to non-normal data, such as asymptotically 
distribution free SEM, require no missing data and would 
unsatisfactorily affect the generalisability of findings as 
well as statistical power in the current analyses. As such, 
we used the MLE approach.
We first used SEM to evaluate the best-fitting measure-
ment model for the following predictors: (1) neurocog-
nition, (2) clinical symptoms and disturbed sleep, and 
(3) alcohol and substance use. Then, we used SEM to 
test the structural model (ie, the relationship between 
predictors and social and occupational functioning) at 
both the single-predictor and the overall levels in order 
to explore potential predictors and delineate unique 
contributions. This was done in a two-step process—first, 
by testing individual predictors and then by testing the 
combined predictors—to quantify the amount of overlap-
ping and unique explanatory power. All analyses used a 
model-trimming approach through an iterative process 
in which non-significant paths with the smallest contri-
bution were sequentially eliminated from a saturated 
model (where all variables were allowed to freely co-vary), 
until a best fitting model was derived to best explain the 
relationships between predictors and functional impair-
ment. Finally, modification indices generated by AMOS 
were used to optimise model fit (ie, to inform which 
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paths and parameters should be added or removed to 
increase model adequacy), although these were only 
used when deemed theoretically meaningful. Residuals 
were allowed to correlate if theoretically justified (eg, 
common measurement variance between neuropsycho-
logical subtests).
Model fit was determined using: (1) the absolute fit χ2 
statistic and (2) the relative fit indices: Bentler Compar-
ative Fit Index (CFI,39 Bentler-Bonnett Non-normed Fit 
Index (NFI40 and Root Mean Square Error of Approxima-
tion (RMSEA41 with 90% CI. An excellent-fitting model is 
typically indicated by a non-significant χ2 test (indicating a 
non-significant difference between the covariance matrix 
of the data and the model), a CFI and NFI of greater 
than 0.90 (indicating that the current model was superior 
to a null model where all paths are constrained to zero), 
and a RMSEA of less than 0.05 with an upper CI bound of 
less than 0.08 (indicating that the error of approximation 
of the model compared with the data was acceptable). In 
small samples (ie, less than 200), the χ2 statistic has been 
shown to be an adequate index of absolute model fit.36 
However, as sample size increases, the χ2 statistic (rela-
tive to a constant df) disproportionately increases, and is 
nearly always significant and inappropriately rejects the 
model irrespective of specified parameters.42 43 An alter-
native solution is to compute a relative χ2/df ratio, with a 
value between 2 and 5 considered excellent to adequate 
fit,42 44–46 although primary emphasis will be placed on the 
relative fit indices as is the established convention.13
Moderator analyses were conducted allowing a model 
to be tested in separate subgroups, comparing the param-
eter estimates to determine how predictors of social 
and occupational functioning in the final model are 
moderated by demographic and clinical factors (these 
were dichotomous to maintain statistical power within 
subgroups for this categorical procedure). For instance, 
the median-split on age was performed to determine 
whether the model held for both younger and older indi-
viduals while maintaining statistical power. We sought to 
specifically test whether predictors in affective-spectrum 
disorders (anxiety, depressive and bipolar disorders) 
were similarly associated with functional impairment 
compared with psychotic, developmental or behavioural 
conditions. We chose to include primary affective disor-
ders (ie, major depression, bipolar disorder or an anxiety 
disorder) as a moderator since these disorders have been 
shown to carry less neurocognitive burden in recent-
onset mood disorders47 48 and, as such, could potentially 
influence the role of neurocognition and the magnitude 
of effects in the statistical models.
results
sample characteristics
In total, 1003 patients were recruited. As shown in tables 1 
and 2, cross-sectional diagnoses were composed of depres-
sive (n=449), bipolar (n=178), psychotic (n=193), anxiety 
(n=109), and developmental or behavioural disorders 
(n=74). The mean age was 20.4 years (SD=4.7), with 
54.0% being female (n=542). Mean educational attain-
ment was 11.7 years (SD=2.5), with an average predicted 
IQ of 101.9 (SD=10.8). The mean SOFAS score was 61.2 
(SD=11.4), indicating moderate levels of impairment. Of 
the participants with medication data available (87.4%, 
n=877), 64.8% were prescribed psychotropic medications 
(n=568). Of these 568 cases, 40.6% were prescribed an 
antidepressant (n=356), 14.8% were prescribed lithium 
or an anticonvulsant (n=130), 33.1% were prescribed any 
antipsychotic (n=290) and 4.8% were prescribed a stimu-
lant (n=42).
single-predictor models
A.  Neurocognition. Inspecting the screen plot, explorato-
ry factor analyses identified two potential latent struc-
tures. The one-factor model was a very good fit for the 
data (χ2=57.3, df=17, p<0.001, CFI=0.980, NFI=0.972, 
RMSEA=0.055, 90% CI 0.040 to 0.071), and was a bet-
ter fit than a two-factor model, whereby trails A, trails 
B and IQ loaded on one latent factor, and IQ, Rey to-
tal, Rey delay, FAS and animals loaded on a second 
Table 2 Neuropsychological functioning across diagnostic subgroups
Depression
(n=449)
Bipolar
 (n=178) 
Psychosis 
(n=193) 
Anxiety 
(n=109) 
Dev/behav 
(n=74)
M SD M SD M SD M SD M SD
IQ* 103.25 10.49 102.82 9.08 99.99 10.47 102.66 9.59 95.30 14.83
Trails A† −0.01 1.32 0.16 1.06 −0.31 1.01 0.12 0.96 −0.03 1.07
Trails B† −0.44 1.53 −0.47 1.92 −1.22 2.23 −0.50 1.59 −0.85 2.16
Rey total† −0.06 1.27 −0.18 1.20 −1.12 1.46 0.09 1.93 −0.48 1.42
Rey delay† 0.03 1.34 −0.27 1.38 −1.07 1.51 0.18 2.29 −0.29 1.22
FAS† −0.31 1.15 −0.04 1.07 −0.56 1.00 −0.37 1.15 −0.86 1.09
Animals† 0.23 1.20 0.45 1.25 −0.28 1.08 0.26 1.17 −0.03 0.94
*Age-adjusted; normative M=100; SD=15.
†Demographically adjusted; normative M=0.00; SD=1.00.
Dev/behav, developmental/behavioural. 
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latent factor (χ2=76.499, df=11, p<0.001, CFI=0.967, 
NFI=0.962, RMSEA=0.077, 90% CI 0.061 to 0.094). 
Factor loadings on the one-factor model were all sig-
nificant and ranged from 0.51 to 0.69 (see figure 1A). 
Neurocognition was a significant contributor to func-
tional level (β=0.39, p<0.001), explaining 15% of the 
variance.
B.  Core clinical symptom dimensions. Only three clinical di-
mensions (depression and anxiety (β=−0.18, p<0.001), 
positive symptoms (β=−0.17, p<0.001) and negative 
symptoms (β=−0.26, p<0.001)) were associated with 
functioning, whereas mania and disorientation were 
not significantly associated (p values >0.05). The mod-
el demonstrated excellent fit (χ2=8.6, df=8, p<0.379, 
CFI=0.999, NFI=0.986, RMSEA=0.009, 90% CI 0.000 to 
0.043), with the three dimensions explaining a total 
of 18% of the variance in functioning (see figure 1B).
C.  Alcohol and substance use. Exploratory factor analyses 
determined that alcohol use did not load with the 
other substance use variables. Only a two-factor latent 
model was possible given the number of observed vari-
ables and statistical constraints. The two-factor mod-
el emerged as an excellent fit for the data (χ2=7.4, 
df=4, p<0.116, CFI=0.995, NFI=0.990, RMSEA=0.033, 
90% CI 0.000 to 0.069), whereby tobacco, cannabis 
and other illicit substance use loaded on a single ‘sub-
stance use’ latent variable as distinct from alcohol 
use (figure 1C). Only substance use was predictive of 
functioning (β=−0.10, p<0.05), explaining 1% of the 
variance.
Final model
In the overall model, all the factors identified in the single 
predictor models remained significant, except for substance 
use (figure 2). Neurocognition showed the strongest unique 
contribution to social and occupational functioning (β=0.36, 
p<0.001); depressive symptoms were next (β=−0.24, p<0.001), 
followed by negative symptoms (β=−0.15, p<0.001) and finally 
positive symptoms (β=−0.10, p<0.001). Together, these four 
clinical features independently accounted for 31% of the 
variance in functioning, with the final model being a very 
good fit for the data (χ2=279.8, df=119, p<0.000, CFI=0.956, 
NFI=0.926, RMSEA=0.037, 90% CI 0.031 to 0.042). Mania, 
disorientation and alcohol and substance use all significantly 
correlated with these four significant features (p values<0.05).
Moderator analyses
 ► Age. As shown in table 3, positive symptoms were no 
longer a significant contributor to functioning in the 
Figure 1 Combined measurement and structural models for functioning and (A) neurocognition, (B) core clinical symptoms 
and (C) alcohol and substance use. All unidirectional (correlation) and directional (regression) paths are significant at p<0.001 
(except path between substance use and functional outcome; where p<0.05) Factor loadings for (A) neurocognition (all p values 
<0.001): IQ (0.58), trails A (−0.51), trails B (−0.55), Rey total (0.69), Rey delay (0.59), FAS (0.57), animals (0.51). Factor loadings 
for (C) substance use (all p values <0.001): tobacco (0.81), cannabis (0.64), other (0.68).
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12-year-old to 20-year-old group (β=−0.06, p=0.178). 
The model with older individuals explained 18% more 
variance in functional impairment than the model 
with younger individuals. This was driven in large part 
by a difference in predictive strength of neurocogni-
tion, whereby it was more predictive in older (β=0.44, 
p<0.001) than younger individuals (β=0.27, p<0.001).
 ► Gender. Positive symptoms were non-significant in 
the male subgroup (β=−0.07, p=0.145), whereas all 
other clinical features remained significant (p values 
<0.001). In females, negative symptoms became 
non-significant (β=−0.07, p=0.105), while the other 
contributors remained significant. The final model 
was comparable across genders in terms of the total 
variance explained.
 ► Primary affective disorder diagnosis. Neurocognition, 
depression and anxiety, and negative symptoms 
remained significant contributors to functional 
level irrespective of affective disorder diagnosis (see 
table 4). By contrast, positive symptoms no longer 
remained significant in both the affective disorder 
(β=−0.63, p=0.097) and psychosis, developmental or 
behavioural disorders (β=−0.102, p=0.123) subgroups. 
An additional 14% of the variance in functioning 
was explained in individuals with a psychotic, devel-
opmental or behavioural disorder, primarily owing 
to the greater predictive strength of neurocognition 
(0.30 vs 0.43, p<0.001).
 ► Medication usage. All factors associated with functional 
impairment remained significant in participants who 
were unmedicated. By contrast, positive symptoms no 
longer remained significant in medicated individuals 
(β=−0.06, p=0.117).
sensitivity analysis
Restricting the full sample to individuals aged 15–25 years 
(n=794) yielded a very good fitting model as well (χ2=240.1, 
df=119, p<0.000, CFI=0.959, NFI=0.924, RMSEA=0.036, 
90% CI 0.029 to 0.042). The explained variance remained 
the same (31% explained). Importantly, all predictors 
remained significant with the same effect sizes, with the 
exception of depression and anxiety, which became slightly 
more predictive (−0.25 → −0.26), and neurocognition, 
which became slightly less predictive (0.36 → 0.35).
Table 3 Analyses of demographic factors (age, gender) as moderators of the relationships between predictors and functional 
outcome in the final model
Age* Gender†
12–20 Years (n=539) 21–36 Years (n=464) Male (n=461) Female (n=542)
β P values β P values β P values β P values
Neurocognition 0.27 0.000 0.44 0.000 0.35 0.000 0.35 0.000
Depression and anxiety −0.28 0.000 −0.22 0.000 −0.23 0.000 −0.30 0.000
Positive symptoms −0.06 0.178 −0.14 0.002 −0.07 0.145 −0.12 0.004
Negative symptoms −0.13 0.005 −0.18 0.000 −0.19 0.000 −0.07 0.105
*12–20 Years (subgroup Model, R2=0.24); 21–36 Years (Subgroup Model, R2=0.40).
†Male (subgroup model, R2=0.32); female (subgroup model, R2=0.29).
Figure 2 Final model. All unidirectional (correlation) and directional (regression) paths are significant at p<0.001 (except 
correlation between substance use and positive symptoms, where p<0.05). Where no path is drawn, it denotes no significant 
relationship between the variables (see figure 1 for all factor loadings of latent variables).
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DIsCussIOn
In a large, clinical, transdiagnostic cohort of youth with 
mental disorders, impaired neurocognition was the clin-
ical feature most significantly associated with functional 
impairment. The role of neurocognition was attenuated 
but still significant in those with an affective disorder 
diagnosis and in the younger age group. The findings are 
relevant as they demonstrate that while neurocognitive 
impairment may undermine functioning in those with 
psychotic disorders, or in chronic or recurrent mental 
disorders, they are not specific to such cases. That is, 
neurocognitive dysfunction has traditionally been argued 
as a core, underlying feature of social and occupational 
impairments in chronic schizophrenia. However, our 
current findings support the burgeoning position that 
the role of neurocognitive deficits cuts across diagnosis 
and clinical stage. Nevertheless, it appears that neuro-
cognitive disturbances are more pronounced in those 
with psychotic, developmental or behavioural disorders, 
converging with evidence of more pronounced cognitive 
deficits in children who will go on to develop psychosis 
compared with those who develop depression or bipolar 
disorder.49–51 Mechanistically, whether neurocognitive 
dysfunction drives functional impairment as a few past 
studies have found,7 28 and is conversely a consequence of 
poor functioning remains to be clarified.
Depressive, anxiety and negative symptom dimensions 
also contributed significantly to level of social and occupa-
tional functioning, supporting previous disorder-specific 
research.11 13 28 Importantly, the contributions of these 
factors to level of functioning were largely independent 
of one another, and do not appear to be moderated by 
other clinical or demographic factors. By comparison, the 
role of positive symptoms diminished considerably in the 
final model. This finding differs from other research in 
psychotic and bipolar disorders, and may reflect the lower 
prevalence of positive symptoms in our cohort in contrast 
to previous studies.11 13 28 However, it was notable that posi-
tive symptoms in older, unmedicated females remained 
significantly associated with functioning. As with neuro-
cognition however, the directionality of findings remains 
unclear, with some evidence suggesting that it may be 
bidirectional in the case of negative symptoms.7 28 52
Intriguingly, neither alcohol and substance use, nor 
sleep disturbances, were directly associated with func-
tional impairment, although these factors remained 
significantly associated with neurocognition and clin-
ical symptoms. Therefore, their role in social and occu-
pational functioning does not appear to be direct, but 
may operate indirectly (eg, substance use may impair 
cognition which in turn may impair functioning). The 
indirect effects of alcohol and substance use, as well as 
sleep and circadian disruptions, warrant more detailed 
examination and causal analysis in longitudinal datasets. 
Moreover, the lack of a direct association between alcohol 
and substance use and functioning may be related to the 
domains of neurocognitive functions currently tested. 
That is, the impact of substance use on functioning may 
be greatest in other neurocognitive functions that are 
more directly linked to driving and maintaining alcohol 
and substance use behaviours, such as those subserved by 
the fear, reward and self-control circuitries not covered 
in the current neuropsychological battery (eg, reward-re-
lated cue learning, habit formation, response inhibition).
The current findings have important implications for 
the transdiagnostic, dimensional approach to psychiatry. 
Research examining the underlying mechanisms of func-
tional impairment in single-diagnosis or dual-diagnosis 
cohorts have been unable to capture the unique contri-
butions of a comprehensive range of neurocognitive, 
symptom, sleep and circadian factors, as well as other 
psychoactive exposures (ie, substance use, prescribed 
medications).22 In particular, neuropsychological studies 
in psychosis have not routinely and concurrently assessed 
depression and anxiety symptoms, hypomania and full-
threshold mania, substance misuse and sleep disturbance. 
That is not to say that categorical, nosological approaches 
have had little to contribute to the field. Indeed, the key 
argument underpinning a DSM approach is to allow for 
comparability across studies and so diagnostic determina-
tions are often necessary. However, in youth, diagnoses 
tend to be unstable1 and, as such, not as useful. One plau-
sible way forward for dimensional psychiatry is to ensure 
that the samples used in transdiagnostic studies are charac-
terised as clearly and as comprehensively as possible,16 53 54 
as was attempted in the present investigation.
Table 4 Analyses of clinical factors (primary affective disorder, medication usage) moderating the relationship between 
predictors and functional outcome in the final model
Primary affective disorder* Medication usage†
Yes (n=736) No (n=267) Nil (n=309) Medicated (n=568)
β P values β P values β P values β P values
Neurocognition 0.30 0.000 0.43 0.000 0.38 0.000 0.38 0.000
Depression and anxiety −0.29 0.000 −0.24 0.000 −0.15 0.007 −0.24 0.000
Positive symptoms −0.06 0.097 −0.10 0.123 −0.22 0.000 −0.06 0.117
Negative symptoms −0.12 0.003 −0.16 0.009 −0.19 0.000 −0.13 0.002
*Yes (subgroup model, R2=0.24); no (subgroup model, R2=0.38).
†Nil (subgroup model, R2=0.38); medicated (subgroup model, R2=0.29).
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In terms of limitations, the current analyses were 
cross-sectional, and future research investigating moder-
ator and mediator analyses would benefit from cross-
lagged, longitudinal path modelling to disentangle 
causality.55 Second, the measures used to index clinical 
symptoms, sleep disturbance, and alcohol and substance 
use were not as comprehensive as is typical in the sleep 
and addiction literatures, and some were not originally 
designed for use in certain clinical disorders which may 
have reduced sensitivity to detect symptoms (eg, mania). 
More detailed examination of these dimensions in the 
future will help more definitively determine whether 
the impact of neurocognition on functioning is as large 
as currently identified. Future studies would also benefit 
from using real-time, ecological momentary assessment 
technologies (eg, substance use monitoring using smart-
phones, actigraphy monitoring of physical activity and 
sleep quality). Third, medication data were not avail-
able for the full sample (12.6% were missing) and, as 
such, the moderating role of medication status requires 
further corroboration (as with the role of medication 
type). Fourth, clinical diagnoses assigned to cases in the 
current study were by treating psychiatrists and future 
studies should consider more structured approaches (eg, 
structured clinical interview for DSM), including consid-
eration of the influence of other comorbid diagnoses (eg, 
personality disorders). Further, the age range included in 
the current study meant that individuals on the opposite 
ends of the age spectrum were at different stages of their 
cognitive and emotional development (eg, executive 
functioning, emotional regulation), although our sensi-
tivity analyses support the argument that our findings 
hold irrespective of age. Further, a phenotype-approach, 
as attempted in the current study, would necessarily 
require converging genetic and neuroimaging evidence 
to ensure that the neurocognitive and symptom dimen-
sions identified as predictive of functioning are linked 
to specific neural circuitries (eg, corticobasal ganglia 
systems56) and genotype which would ultimately facilitate 
the development of next-generation and neuroscience-in-
formed pharmacotherapies. Finally, it remains to be seen 
whether the current findings hold in future studies with 
less missing data, as well as in studies using measures or 
approaches that can circumvent potential biases stem-
ming from non-normally distributed data.
This was the first study to examine a broad range of 
illness-related factors and associations with functional 
impairment in a well-powered and broadly transdiag-
nostic, clinical cohort of more than one thousand young 
people with mental illness. A significant contribution 
of the present findings to the established literature 
was evidence showing that neurocognition is a strong 
and reliable, unique predictor of social and occupa-
tional functioning irrespective of diagnosis—in a cohort 
predominantly composed of affective disorders which 
has not been previously demonstrated before at this 
scale. As such, the functional importance of neurocog-
nitive functions clearly extends beyond the psychosis 
and developmental disorders spectrums and appears to 
become more pronounced with increasing age. Future 
studies should attempt to replicate these findings, as well 
as to clarify the directions of cause and effect.
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